Clinical Application of A New In Vitro High-throughput Drug Sensitivity Screening Technology in Individualized Medication of Relapsed Refractory Acute Myeloid Leukemia Patients

Abstract

Objective To explore the clinical value of new high-throughput drug sensitivity (HDS) screening technology in the individualized medication of relapsed refractory acute myeloid leukemia patients. Methods We collected bone marrow samples of 19 patients with relapsed and refractory acute myeloid leukemia, enriching and culturing leukemic cancer cells by HDS technology. In vitro efficacy evaluation of 15 single drugs and 17 chemotherapy regimens was carried out according to the blood peak concentration corresponding to clinical dose. The drugs and programs were divided into four levels: high, medium, low and insensitive, according to the inhibition rate of cell activity detected and calculated by Celltiter-Glo based chemiluminescence, then we observed the clinical remission rate. Results Among the 19 patients, there were 4 cases of non-remission (NR), 4 cases of complete remission (CR) and 11cases of partial remission (PR), and the overall remission rate was 78.94%. The sensitivity frequency of DAE, DAC, HAD and HD-DA schemes were higher than 68%. Conclusion The high-throughput drug sensitivity screening technology is a rapid, efficient and low-cost detection technology, with good clinical application value in individualized medication of relapsed refractory AML patients, worthy of clinical promotion in the post genomic era.

Keywords

• drug sensitivity
• aml
• high-throughput
• hds